Why this study matters

Stargardt disease is an inherited retinal disease most often caused by disease-causing changes in both copies of the ABCA4 gene. Although it is often described as a macular disease—meaning it affects the central retina used for detailed vision—its effects can vary greatly between individuals. Some people have disease largely centered in the macula, while others develop changes that extend further into the peripheral retina.

Understanding why these differences occur is important for patients, families, and researchers. It may help explain differences in vision loss, identify which retinal cells are most affected in particular forms of disease, and guide the development of treatments designed for distinct disease patterns.

In this 2026 iScience study, researchers created laboratory models from two people with phenotypically different forms of Stargardt disease. Using induced pluripotent stem cells (iPS cells), they produced retinal pigment epithelium (RPE) cells, photoreceptor precursor cells, and three-dimensional retinal organoids. These patient-derived models allowed the team to examine how ABCA4-related disease processes differed at the cellular level.

Building a Retina Model From Patient Cells

Induced pluripotent stem cells are cells that can be generated from an individual and then directed to develop into different cell types in the laboratory. In this study, the researchers used iPS cell lines from two Stargardt disease patients to make cells relevant to the retina.

The RPE is a supportive layer of cells beneath the photoreceptors, the light-sensing cells of the retina. One of the RPE’s essential jobs is to take up and break down used portions of photoreceptor outer segments. These outer segments contain the machinery photoreceptors use to capture light and must be continually renewed throughout life.

Retinal organoids are laboratory-grown, three-dimensional structures that reproduce certain features of developing retinal tissue. While they are not complete human retinas, they enable researchers to observe disease-related changes in photoreceptor-like cells over time.

Key Findings: Differences in RPE Function

The most striking RPE findings were seen in cells from the patient whose Stargardt disease included peripheral retinal involvement. Compared with the other patient-derived cells, these RPE cells had lower ABCA4 expression. They also showed reduced ability to engulf and digest photoreceptor outer segments.

This impaired clearance was accompanied by accumulation of lipid byproducts. In practical terms, the study suggests that when RPE cells cannot efficiently process material shed by photoreceptors, waste products may build up. This could place additional stress on the retina and may be particularly relevant in forms of Stargardt disease that extend beyond the macula.

The findings give the RPE a potentially larger role in Stargardt disease than might be appreciated from a photoreceptor-centered view alone. The authors propose that poor outer-segment clearance by RPE cells may be linked to peripheral disease features in ABCA4-associated macular dystrophy.

What the Retinal Organoids Showed

At 45 weeks of maturation, retinal organoids from both patients shared several changes associated with retinal disease. Their photoreceptor segments were stunted, meaning these structures did not develop normally. The organoids also contained more rods, one of the two main classes of photoreceptors.

In addition, both patient-derived organoids showed activation of caspase-3, a marker associated with cellular degeneration, as well as lipofuscin accumulation. Lipofuscin is a material that can accumulate in retinal cells when certain byproducts are not adequately cleared. Its presence in these models is notable because abnormal buildup of retinal byproducts is a central feature of Stargardt disease biology.

Together, the organoid findings indicate that despite differences in patient phenotype, both ABCA4-related disease models developed signs of photoreceptor stress and degeneration.

Implications for Treatment Development

This study did not test a treatment. Its value lies in clarifying disease mechanisms and providing patient-derived platforms that may be useful for future treatment research.

The results support the idea that treatment approaches may need to consider both photoreceptors and the RPE. Strategies intended to improve ABCA4-related retinal health may need to address not only harmful byproduct accumulation in photoreceptor cells, but also the RPE’s ability to process photoreceptor outer segments and manage lipid waste.

The study also highlights the importance of patient-specific models. Stargardt disease is not identical in every person with ABCA4 variants. Models made from people with different clinical patterns may help researchers understand which cellular changes are shared across disease forms and which are associated with more extensive retinal involvement.

A More Personalized Research Future

The ability to grow RPE cells and retinal organoids from individual patients is expanding the Stargardt disease research landscape. These systems can connect a person’s genetic and clinical characteristics with measurable changes in retinal cells.

This work points toward a future in which researchers can investigate why particular ABCA4 variants lead to different disease patterns and use those insights to develop more targeted therapeutic strategies. By showing that impaired RPE clearance may be especially relevant to peripheral disease features, the study adds an important piece to the ongoing effort to understand—and ultimately treat—the full range of Stargardt disease.